

Sub
C1
sterile-filtering, dispensing into injection vials and
lyophilizing the solution.

Sub
C1
B
13. The method according to Claim 12, wherein the
peptides employed are LHRH analogues or their salts.

14. The method according to Claim 12, wherein the
peptides employed are LHRH antagonists or their salts.

15. The method according to Claim 14, wherein the LHRH
antagonist salts employed are cetorelix salts.

16. The method according to one of claims 12-15, wherein
said peptide salt is cetorelix acetate.

Sub
C2
17. The method according to Claim 12, wherein the
bulking agent used is a hexitol, urea or sodium chloride in an
amount from 10-500 parts by weight per 1 part by weight of
cetorelix.

18. The method according to claim 17, wherein said
bulking agent is a hexitol selected from the group consisting
of mannitol, glucitol, sorbitol, D-sorbitol, dulcitol, allitol
and iditol,